Back to Agenda
Session 1 - Opening Plenary Session
Session Chair(s)
Norman Stockbridge, MD, PhD
Director, Division of Cardiology and Nephrology, OND, CDER
FDA, United States
OPENING PLENARY SESSION
Speaker(s)
QT EXPERIENCE AS A MODEL FOR FURTHERING COLLABORATIVE APPROACHES/RESEARCH IN CV SAFETY ASSESSMENT OF T2DM
Christine E. Garnett, PharmD
FDA, United States
Associate Director, Pharmacometric Operations,OCP, CDER
TYPE 2 DIABETES: CLINICAL IMPLICATIONS, CV MANIFESTATIONS, AND EPIDEMIOLOGY
Anders Svensson, MD, PhD
F. Hoffmann-La Roche AG, Switzerland
Head of Global Clinical Development - Metabolism
GLYCEMIA CONTROL – EVIDENCE FOR IMPACTS ON CARDIOVASCULAR AND MORTALITY OUTCOMES IN TYPE 2 DM
Denise Simons-Morton, MD, PhD
National Heart, Lung and Blood Institute, United States
Senior Scientific Advisor, Division of Cardiovascular Sciences (DCVS)
THE CLINICAL EVIDENCE THAT T2DM DIABETIC DRUGS CAN INCREASE CARDIOVASCULAR RISK AND POTENTIAL MECHANISMS
Steven E. Nissen, MD
Cleveland Clinic Foundation, United States
Chairman, Department of Cardiovascular Medicine
PANEL DISCUSSION: PHARMACEUTICAL TREATMENT OF DIABETES MELLITUS – POSITIVE OUTCOMES AND CV RISK – Includes All Speakers Above
Louis Lange, MD, PhD
CV Therapeutics, Inc., United States
Past Chief of Cardiology, Washington School of Medicine, Jewish Hospital
Have an account?